(Q31924533)

English

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

0 references

1 reference

based on heuristic

inferred from title

polycystic ovary syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

polycystic ovary

1 reference

based on heuristic

inferred from title

author name string

Vandermolen DT

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Ratts VS

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Evans WS

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Stovall DW

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Kauma SW

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Nestler JE

6

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

language of work or name

0 references

publication date

1 February 2001

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Fertility and Sterility

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

75

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

310-315

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

An extended regimen of clomiphene citrate in women unresponsive to standard therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Serum dehydroepiandrosterone sulfate and the use of clomiphene citrate in anovulatory women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Clinical and laboratory predictors of clomiphene response

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Effects of insulin-like growth factors I and II and insulin on the immortalized hypothalamic GTI-7 cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901675-7

7 January 2021

Identifiers

10.1016/S0015-0282(00)01675-7

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31924533&oldid=1588410531"